Endocrine/metabolic Supercede’s SPCD-4-79 demonstrates preclinical efficacy in DIO mice June 25, 2025 No Comments Supercede Therapeutics Inc. has released preclinical efficacy data on its small-molecule inhibitor of the Activin receptor type II (ACTRII) to treat obesity. Read More